UCLA Advanced Lung Disease and Lung Transplantation Symposium 2023 Brochure (PDF)

The 2023 UCLA Advanced Lung Disease and Lung Transplantation Symposium is a hybrid virtual and in-person conference, organized by UCLA Health, the UCLA Office of Continuing Medical Education, and a multi-disciplinary group of speakers. The goal of the program is to provide updated information on state-of-the-art therapies available for patients with end-stage lung disease, including medical and interventional approaches, as well as lung transplantation.

In the event that in-person attendance is canceled or capacity limits modified per CDC or public health guidelines, the UCLA Advanced Lung Disease and Lung Transplantation Symposium will be modified accordingly or presented entirely as a live virtual activity.

Target Audience

This conference is targeted at pulmonologists, cardiologists, critical care physicians, internists, cardiac and thoracic surgeons as well as allied health professionals who care for patients with advanced lung disease or refer patients for lung transplantation.

REGISTRATION INFORMATION

General Information

The UCLA Advanced Lung Disease and Lung Transplantation Symposium will also be available through a live virtual meeting web platform.

• Attendees who choose to attend the live virtual activity will receive a virtual meeting link and password to access the live virtual conference.
• All registrants (live or virtual) will be provided the opportunity to review recorded sessions up to 3 weeks following the conference.
• Attendees will be awarded CME credit commensurate with the extent of their participation in the live activity (either in-person or virtual). The recorded sessions are not certified for CME credit.
• Proof of vaccination will be required to attend the in-person meeting.

Course Fees

In-Person Attendance

includes access to the course materials, breakfast and lunch.

• $50 MD/DO
• $40 Nurse, Nurse Practitioner & Allied Health Professionals
• $25 Student/Trainees

Virtual Attendance

includes access to the live-stream virtual conference. All registrants (live or virtual) will receive access to the conference recordings up to 3 weeks following the program.

• $50 MD/DO
• $40 Nurse, Nurse Practitioner & Allied Health Professionals
• $25 Student/Trainees

Refunds

Due to the low enrollment fee, no refunds will be provided for this program

Questions

If you have questions about enrollment, please call (310) 794-2620 or email uclacme@mednet.ucla.edu.

OBJECTIVES 

At the conclusion of the program participants will be able to:

• Identify when to refer patients for lung transplantation and gain an understanding of recent advances in the field that may allow patients who were previously not eligible for transplantation to be considered.
• Identify the importance of psychosocial support after lung transplantation.
• Recognize how health care disparities affect those with advanced lung disease.
• Be familiar with the diagnostic best practices when evaluating a patient with interstitial lung disease, including the use of multidisciplinary discussion.
• Implement current state-of-the-art diagnostic tools and treatment strategies in managing patient with sarcoidosis.
• Gain a better understanding of the complex interaction between interstitial lung disease and pulmonary vascular disease.

ACCREDITATION

The Office of Continuing Medical Education, David Geffen School of Medicine at UCLA is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Office of Continuing Medical Education, David Geffen School of Medicine at UCLA, designates this live activity for a maximum of 5.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The California State Board of Registered Nursing accepts courses approved for the AMA PRA Category 1 Credit(s)™ as meeting the continuing education requirements for license renewal. Nurses from states other than California should inquire with their local State Board for specific continuing education policies.

DISCLOSURES

The FDA has issued a concept paper that classifies commercial support of scientific and educational programs as promotional unless it can be affirmed that the program is “truly independent” and free of commercial influence. In addition to independence, the FDA requires that non-promotional, commercially supported education be objective, balanced and scientifically rigorous. The policy further states that all potential conflicts of interest of the CME staff and faculty be fully disclosed to the program’s participants. In addition, Accreditation Council for Continuing Medical Education policy mandates that the provider adequately manage all identified potential conflicts of interest prior to the program. UCLA fully endorses the letter and spirit of these concepts.